Floatz logo

Bosentan

Scleroderma, Systemic

ActelionSmall moleculePhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Scleroderma, Systemic cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3BB
Iloprost
National Center for Research Resources (NCRR)
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3B
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2B
RECOMBINANT HUMANISED IgG1 KAPPA ANTI-ONCOSTATIN M MONOCLONAL ANTIBODY GSK2330811
GlaxoSmithKline
Phase 2B

View all 41 →

Same molecule, other indications

Bosentan is also rated in:

SclerodermaDormant
B
Indicative ·
63 / 100
View asset →
idiopathic pulmonary fibrosisDormant
B
Indicative ·
62 / 100
View asset →
pulmonary hypertensionDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →